DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Walter E. Washington Convention Center

2025 年 06 月 15 日 7:15 上午 - 2025 年 06 月 15 日 4:30 下午

801 Allen Y. Lew Place, NW, Washington, DC 20001-3614, USA

Cell and Gene Therapy Summit

Join multi-stakeholder dialogue, identifying the barriers to progress and charting the best path forward in global regulatory harmonization for cell and gene therapies.

Session 2: Panel Discussion on the Challenges of Global Development for Cell and Gene Therapies

Session Chair(s)

Raju  Kucherlapati

Raju Kucherlapati

Paul C. Cabot Professor of Genetics and Professor of Medicine, Harvard Medical School, United States

Global regulatory frameworks have evolved in tandem with the rapid advancements in cell and gene therapies. This session will review the latest regulatory guidance documents from global regulatory agencies and identify strategies that have been used to address key challenges in the field, such as protecting patient safety and product efficacy. Given the need for efficiency in a fast-moving landscape yet a balance of regulatory rigor, panelists will draw attention to how existing regulatory frameworks have adapted to the increase of cell and gene therapies and recent opportunities for global harmonization of regulatory processes. The session will highlight examples of international collaboration, how approval pathways have been streamlined, and regulatory trends that are molding the future of cell and gene therapy.

Learning Objective :
  • Differentiate global harmonization efforts and understand the role of international collaboration in approval pathways
  • Evaluate the impact of recent global regulatory guidance on cell and gene therapy development
  • Identify key regulatory challenges in balancing safety, efficacy, and efficiency

Speaker(s)

Renata Miranda Parca, AHIP

Renata Miranda Parca, AHIP

Health regulatory specialist, ANVISA, Brazil

Speaker

Yasuhiro  Kishioka, PHD

Yasuhiro Kishioka, PHD

Review Director, Office of Cellular and Tissue-based Products, Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Speaker

Nicole  Verdun, MD

Nicole Verdun, MD

Director, Office of Therapeutic Products, CBER, FDA, United States

Speaker

Christine  Ho, RPH

Christine Ho, RPH

Director, Advanced Therapy Products Branch, Health Sciences Authority, Singapore, Singapore

Speaker

Julian  Beach, MBA

Julian Beach, MBA

Interim Executive Director, Healthcare Quality and Access, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Speaker

Evdokia  Korakianiti, PHD, MSC

Evdokia Korakianiti, PHD, MSC

Head of Quality and Safety of Medicines, European Medicines Agency, Netherlands

Speaker

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。